Sound corporate governance and high standards of ethical behavior are essential to company success, and in maintaining the trust and confidence of our stakeholders. Corporate governance at Idorsia is designed to promote the long-term interests of our shareholders, maintain internal checks and balances, strengthen management accountability and foster responsible decision‑making.

Our Code of Business Conduct underpins our commitment to integrity and sets out fundamental rules for interacting with others as we drive our business forward. Supporting policies, standard operating procedures and guidelines provide more detail on how our high-level commitments should be applied in practice. Compliance with the Code is mandatory, all Idorsia employees are trained on its implementation.

Idorsia’s Board and management are commited to ensuring that responsible business and sustainability considerations are integrated into everyday business thinking and decision-making throughout the company. With products on the market, having the correct guiding principles, along with appropriate checks and balances, becomes even more important. As a result the company has strengthened the compliance function to drive safe and appropriate use of our medicinal products.

Clinical trials are essential to the development of innovative medicines. Idorsia is committed to the highest quality and ethical standards in all our clinical research. Our trials are performed in accordance with internationally accepted guidelines, and protocols are evaluated by independent review boards and ethics committees prior to study initiation. We are also dedicated to enhancing public health through responsible clinical trial information transparency which respects our proprietary information, patients’ privacy, laws and regulations. In addition to our existing clinical trial disclosure activities, we are committed to implementing the Principles for Responsible Clinical Trial Data Sharing jointly issued by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Governance Report 2023

Idorsia’s Corporate Governance Report follows the structure of the SIX Swiss Exchange Directive on Information relating to Corporate Governance and takes into account the Swiss Code of Best Practice for Corporate Governance issued by economiesuisse.

Governance report


Group Compliance Officer

Hegenheimermattweg 91

4123 Allschwil


Whistleblower hotline:

  • Switzerland: 0800 110 007
  • USA: (833) 222-3891 (anonymous reporting channel)
  • Outside Switzerland and USA: +41 58 844 0106

Quality documentation

To ensure that our employees understand how important it is to work in a compliant, ethical and transparent manner, Idorsia has implemented a number of policies, guidelines, and standard operating proceedures covering the breadth of its business areas. Access to these documents is ensured for all employees via an electronic quality-management system.